In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Latest From Actavis Group

US Supreme Court Will Not Review Contrave Case

The US Supreme Court has turned down a request by Teva’s Actavis to review a ruling that upheld a patent protecting Nalpropion’s Contrave until 2030, despite the generics firm pointing out that the exact terms of a patent claim were not present in its specification.

Intellectual Property Legal Issues

US FDA Finds Negligible Cancer Risks In Metformin Products

The US FDA finds metformin meets NDMA impurity threshold and urges diabetics to continue taking it.

Manufacturing Quality

Diclofenac Reverse-Switched In Norway As Risks Outweigh Benefits

Norway becomes the latest country to reverse-switch diclofenac in response to a 2018 study linking low doses of the drug to cardiovascular adverse events. 

Drug Safety Regulation

Sweden Reverse-Switches Diclofenac Over Cardio Fears

Oral diclofenac will no longer be available without a prescription in Sweden after the national drug regulator judged that the potential adverse event risks were too high to justify continued OTC supply. Products from GSK and Mylan will be affected by the decision.

Regulation Prescription To Otc Switch
See All

Company Information